Researchers are conducting a phase 3 trial to compare sotorasib plus panitumumab with investigator’s choice of therapy in patients with previously treated, KRAS p.G12C-mutated metastatic colorectal cancer.
Researchers are conducting a phase 3 trial to compare standard care with combination tucatinib, trastuzumab, and chemotherapy as first-line treatment in HER2-positive, unresectable or metastatic colorectal cancer.
Researchers are comparing nivolumab monotherapy, nivolumab plus ipilimumab, and investigator’s choice of chemotherapy in MSI-H/dMMR, recurrent or metastatic colorectal cancer.
Researchers are conducting a phase 3 trial to compare XL092 plus atezolizumab with regorafenib alone in MSS/MSI-low metastatic colorectal cancer.
Surgical resection generally improves long-term outcomes over local resection in high-risk, T1 colorectal cancer, a study suggests.
Among African-American cancer survivors, experiencing discrimination is associated with frailty, a study suggests.
The prevalence of hand-foot syndrome after chemotherapy is high among patients with colorectal cancer, according to researchers.
Compared with standard care, preoperative short-course RT followed by chemotherapy can decrease distant metastasis in patients with high-risk LARC.
Studies suggest that ctDNA testing has prognostic value in colorectal cancer, but more research is needed before it can be used in practice.
Cancer patients living in nursing homes are more likely to receive aggressive end-of-life care and die in the hospital, a study suggests.
